Female Reproductive System Adenocarcinoma

Female Reproductive System Adenocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

454 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 158
Recruiting: 74
Ph III recruiting: 10
Growth YoY: +19%
Industry share: 19%
Top sponsor: National Cancer Institute (NCI)
Termination share: 33.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (59)

clinicaltrialsPublishedShowing 451–454 of 454 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00025467	Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer	completed	Phase 2	60	National Cancer Institute (NCI)NIH	1	Jan 24, 2013	clinicaltrials
NCT00052585	Gefitinib and Combination Chemotherapy in Treating Patients With Advanced or Recurrent Colorectal Cancer	terminated	Phase 2	50	National Cancer Institute (NCI)NIH	1	Jan 16, 2013	clinicaltrials